
Sign up to save your podcasts
Or
Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/
IV. DOAC Failure
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
https://doi.org/10.1212/WNL.0000000000207422
V. Primary or Secondary Prevention
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
4.9
826826 ratings
Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/
IV. DOAC Failure
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
https://doi.org/10.1212/WNL.0000000000207422
V. Primary or Secondary Prevention
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
130 Listeners
13 Listeners
319 Listeners
160 Listeners
494 Listeners
18 Listeners
272 Listeners
3,321 Listeners
87 Listeners
135 Listeners
1,082 Listeners
54 Listeners
186 Listeners
515 Listeners
320 Listeners
59 Listeners
25 Listeners
8 Listeners
415 Listeners
363 Listeners